Morphine to methadone conversion: An interpretation of published data

American Journal of Hospice and Palliative Medicine

Volumn 28, Issue 2, 2011, Pages 135-140

  Pollock, Ashley B ^a   Tegeler, Monica L ^a   Morgan, Vickie ^a   Baumrucker, Steven J ^a,b  

^a ETSU College of Medicine and Holston Valley Medical Center   (United States)

^b Palliative Medicine Associates   (United States)

Author keywords

Ayonrinde; chronic pain; conversion; delta receptor; methadone; Morley Makin; morphine; mu receptor; NMDA receptor; opioid rotation; Plonk method; review

Indexed keywords

METHADONE; MORPHINE; MU OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NARCOTIC ANALGESIC AGENT;

ARTICLE; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; METHODOLOGY; PAIN; PALLIATIVE THERAPY;

ANALGESICS, OPIOID; HUMANS; METHADONE; MORPHINE; PAIN; PALLIATIVE CARE; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, OPIOID, MU;

EID: 79952148418     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/1049909110373508     Document Type: Article

References (34)

1. Lawlor P., Turner K., Hanson J., Bruera ED Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer. 1998;82(6):1167-1173.
2. Mancini I., Lossignol D., Body JJ Opioid switch to oral methadone in cancer pain. Curr Opin Oncol. 2000;12(4):308-313.
3. Ripamonti C., Groff L., Brunelli C., Polastri D., Stavrakis A., De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol. 1998;16(10):3216-3221.
4. Tse DM, Sham MM, Ng DK, Ma HM An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population. Palliat Med. 2003;17(2):206-211.
5. Plonk W. Simplified Methadone Conversion. J Palliat Med. 2005; 8(3):478-479.
6. Davis M., Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer. 2001;9(2): 73-83.
7. Morley J., Makin M. The use of methadone in cancer pain poorly responsive to other opioids. Pain Rev. 1998;5(1):51-58.
8. Auret K., Goucke R., Ilett KF, Page-Sharp M., Boyd F., Oh TE Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. Ther Drug Monit. 2006; 28(3):359-366.
9. Sjogren P., Jensen N., Jensen TS Disappearance of morphine-induced hyperalgesia after discontinuing of substitituting morphine with other opioid agonists. Pain. 1994;59(2):313-316.
10. Leng G., Finnegan MJ Successful use of methadone in nociceptive cancer pain unresponsive to morphine. Palliat Med. 1994; 8(2):153-156.
11. Crews J., Sweeney N., Denson DD Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain. Case presentations and discussion of incomplete cross-tolerance among opioid agonist analgesics. Cancer. 1993;72(7):2266-2272.
12. Moryl N., Kogan M., Comfort C., Obbens E. Methadone in the treatment of pain and terminal delirum in advanced cancer patients. Palliat Support Care. 2005;3(4):311-317.
13. Patanwala A., Duby J., Waters D., Erstad BL Opioid conversions in acute care. Ann Pharmacother. 2007;41(2):255-266.
14. Gammaitoni A., Fine P., Alvarez N., McPherson ML, Bergmark S. Clinical application of opioid equianalgesic data. Clin J Pain. 2003;19(5):286-297.
15. Ripamonti C., Zecca E., Bruera E. An update on the clinical use of methadone for cancer pain. Pain. 1997;70(2-3):109-115.
16. Bruera E., Watanabe S., Fainsinger RL, Spachynski K., Suarez-Almazor M., Inturrisi C. Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain. 1995;62(2):141-146.
17. Manfredi P., Borsook D., Chandler SW, Payne R. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations. Pain. 1997;70(1):99-101.
18. Mancini I., Lossignol D., Body JJ Opioid switch to oral methadone in cancer pain. Curr Opin Oncol. 2000;12(4):308-313.
19. Fisher K., Stiles C., Hagen NA Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breatkthrough pain: a pilot study. J Pain Symptom Manage. 2004;28(6): 619-625.
20. Ripamonti C., Groff L., Brunelli C., Polastri D., Stavrakis A., De Conno F. Switching from morphine to oral methadone in treating cancer: what is the equianalgesic dose ratio? J Clin Oncol. 1998; 16(10):3216-3221.
21. Mercadante S., Casuccio A., Agnello A., Serretta R., Calderone L., Barresi L. Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. J Clin Oncol. 1998;16(11):3656-3661.
22. Zech D., Grond S., Lynch J., Hertel D., Lehmann KA Validation of World Health Organization Guidelines for cancer pain relief: a 10-year propspective study. Pain. 1995;63(1):65-76.
23. Fainsinger R., Schoeller T., Bruera E. Methadone in the management of cancer pain: a review. Pain. 1993;52(2):137-147.
24. de Stoutz N., Bruera E., Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage. 1995;10(5):378-384.
25. Ebert B., Andersen S., Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett. 1995;187(3):165-168.
26. Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clinical Pharmacol Ther. 1987; 41(4):392-401.
27. Gourlay G., Cherry D., Cousins MJ A comparative study of the efficacy and pharmacokinetic considerations of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain. 1986;25(3):297-312.
28. De Conno F., Groff L., Brunelli C., Zecca E., Ventafridda V., Ripamonti C. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol. 1996;14(10):2836-2842.
29. Hagen N., Wasylenko E. Methadone: outpatient titration and monitoring strategies in cancer patients. J Pain Symptom Manage. 1999;18(5):369-375.
30. Ripamonti C., De Conno F., Groff L.,et al.Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Ann Oncol. 1998;9(1): 79-83.
31. Fishman S., Wilsey B., Mahajan G., Molina P. Methadone reincarnated: novel clinical applications with realated concerns. Pain Med. 2002;3(4):339-348.
32. Ayonrinde OT, Bridge DT The rediscovery of methadone for cancer pain management. Med J Aust. 2000;173(10): 536-540.
33. Wheeler W., Dickerson E. Clinical applications of methadone. Am J Hosp Palliat Care. 2000;17(3):196-203.
34. Ayonrinde O., Bridge D. The rediscovery of methadone for cancer pain management. Med J Aust. 2000;173(10):536-540.